他汀类药物对糖尿病及心血管疾病风险人群非高密度脂蛋白胆固醇疗效比较:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入42项随机对照试验共20193名成人糖尿病患者,评估不同种类和强度他汀对非高密度脂蛋白胆固醇(non-HDL-C)的影响。结果显示,瑞舒伐他汀中高强度、辛伐他汀和高强度阿托伐他汀降低non-HDL-C幅度最大;阿托伐他汀中强度较安慰剂显著降低非致死性心肌梗死风险(RR=0.57,95%CI 0.43-0.76)。
要点
- 瑞舒伐他汀中、高强度及辛伐他汀、阿托伐他汀高强度降低non-HDL-C幅度最大。
- 阿托伐他汀中强度较安慰剂显著降低非致死性心肌梗死风险(RR=0.57,95%CI 0.43-0.76)。
- 停药、非致死性卒中和心血管死亡方面未见显著差异。
核心结论
- 瑞舒伐他汀中、高强度及辛伐他汀、阿托伐他汀高强度降低糖尿病患者non-HDL-C最有效,可为选择他汀种类和强度提供指导。
研究设计与样本
- 系统综述与网状Meta分析,检索Medline、Cochrane对照试验中心注册库和Embase自建库至2021年12月1日。
- 纳入比较不同种类和强度他汀(含安慰剂)的随机对照试验,对象为1型或2型糖尿病成人。
- 共42项随机对照试验涉及20193名成人,其中11698名纳入Meta分析。
- 采用贝叶斯网状Meta分析(随机效应)评估他汀强度(低、中、高)对non-HDL-C的疗效,以均数差和95%可信区间表示。
- 对主要心血管事件风险较高患者与低或中等风险患者进行亚组分析,并应用CINeMA框架评价证据确定性。
主要发现
- 与安慰剂相比,瑞舒伐他汀高强度降低non-HDL-C -2.31 mmol/L(95%可信区间 -3.39至-1.21),中强度 -2.27(-3.00至-1.49)。
- 与安慰剂相比,辛伐他汀高强度降低non-HDL-C -2.26 mmol/L(-2.99至-1.51),阿托伐他汀高强度 -2.20(-2.69至-1.70)。
- 在4670名主要心血管事件风险较高患者中,阿托伐他汀高强度降低non-HDL-C -1.98 mmol/L(-4.16至0.26),累积排序曲线下面积64%。
- 降低LDL-C最有效的方案为辛伐他汀高强度(-1.93,-2.63至-1.21)和瑞舒伐他汀高强度(-1.76,-2.37至-1.15)。
- 与安慰剂相比,阿托伐他汀中强度显著降低非致死性心肌梗死(相对风险=0.57,置信区间0.43至0.76,n=4项研究);停药、非致死性卒中和心血管死亡未见显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of different statin treatments by intensity on levels of non-high density lipoprotein cholesterol (non-HDL-C) for the prevention of cardiovascular disease in people with diabetes. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Medline, Cochrane Central Register of Controlled Trials, and Embase from inception to 1 December 2021. REVIEW METHODS: Randomised controlled trials comparing different types and intensities of statins, including placebo, in adults with type 1 or type 2 diabetes mellitus were included. The primary outcome was changes in levels of non-HDL-C, calculated from measures of total cholesterol and HDL-C. Secondary outcomes were changes in levels of low density lipoprotein cholesterol (LDL-C) and total cholesterol, three point major cardiovascular events (non-fatal stroke, non-fatal myocardial infarction, and death related to cardiovascular disease), and discontinuations because of adverse events. A bayesian network meta-analysis of statin intensity (low, moderate, or high) with random effects evaluated the treatment effect on non-HDL-C by mean differences and 95% credible intervals. Subgroup analysis of patients at greater risk of major cardiovascular events was compared with patients at low or moderate risk. The confidence in network meta-analysis (CINeMA) framework was applied to determine the certainty of evidence. RESULTS: In 42 randomised controlled trials involving 20 193 adults, 11 698 were included in the meta-analysis. Compared with placebo, the greatest reductions in levels of non-HDL-C were seen with rosuvastatin at high (-2.31 mmol/L, 95% credible interval -3.39 to -1.21) and moderate (-2.27, -3.00 to -1.49) intensities, and simvastatin (-2.26, -2.99 to -1.51) and atorvastatin (-2.20, -2.69 to -1.70) at high intensity. Atorvastatin and simvastatin at any intensity and pravastatin at low intensity were also effective in reducing levels of non-HDL-C. In 4670 patients at greater risk of a major cardiovascular events, atorvastatin at high intensity showed the largest reduction in levels of non-HDL-C (-1.98, -4.16 to 0.26, surface under the cumulative ranking curve 64%). Simvastatin (-1.93, -2.63 to -1.21) and rosuvastatin (-1.76, -2.37 to -1.15) at high intensity were the most effective treatment options for reducing LDL-C. Significant reductions in non-fatal myocardial infarction were found for atorvastatin at moderate intensity compared with placebo (relative risk=0.57, confidence interval 0.43 to 0.76, n=4 studies). No significant differences were found for discontinuations, non-fatal stroke, and cardiovascular deaths. CONCLUSIONS: This network meta-analysis indicated that rosuvastatin, at moderate and high intensity doses, and simvastatin and atorvastatin, at high intensity doses, were most effective at moderately reducing levels of non-HDL-C in patients with diabetes. Given the potential improvement in accuracy in predicting cardiovascular disease when reduction in levels of non-HDL-C is used as the primary target, these findings provide guidance on which statin types and intensities are most effective by reducing non-HDL-C in patients with diabetes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42021258819.
引用
- Hodkinson A, Tsimpida D, Kontopantelis E, et al. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022. PMID: 35331984. doi:10.1136/bmj-2021-067731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。